Biology subjects

Simic, G.

Publications and source records attributed to Simic, G..

2 recordsLinked to original sources

bioRxiv2020

Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain

A population of >6 million people worldwide at high risk of Alzheimers disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of {beta}-amyloid-(A{beta})-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from non-invasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar A{beta} deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome-21-gene BACE2, but prevented by combined chemical {beta} and {gamma}-secretase inhibition. We found that T21-organoids secrete increased proportions of A{beta}-preventing (A{beta}1-19) and A{beta}-degradation products (A{beta}1-20 and A{beta}1-34). We show these profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by BACE2-trisomy and cross-inhibited by clinically trialled BACE1-inhibitors. Combined, our data prove the physiological role of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in [~]30% of people with DS. We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.

neuroscience↗

bioRxiv2018

Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau immunoreactive protein species

Recent data suggest that early stages of Alzheimers disease (AD) are characterized by an abnormally high phosphorylation of microtubule-associated protein tau and truncation of its C-terminus. Tau hyperphosphorylation may result from the downregulation of phosphatases, especially protein phosphatase 2A. In an attempt to model and analyze these molecular events we treated SH-SY5Y cells with okadaic acid (OA), an inhibitor of protein phosphatases. In addition to the low molecular weight tau, such treatment lead to the appearance of heat-stable protein species with apparent high molecular weight around 100 kDa, which were immunoreactive to tau antibodies against phosphorylated Ser202 and phosphorylated Ser396. Based on the observation that high molecular weight tau-immunoreactive proteins (HMW-TIP) correspond to the predicted size of two monomers of tau, one possibility is that HMW-TIP represent tau oligomers. The absence of HMW-TIP detection by anti-total tau antibodies used may be a consequence of epitope masking, or a combination of epitope masking and protein truncation. We noted the stability of HMW-TIP in the presence of strong denaturing agents, such as urea and guanidine, as well as upon partial dephosphorylation by the alkaline phosphatase. Moreover, as HMW-TIP did not dissociate the presence of {beta}-mercaptoethanol, it was also independent from disulfide bonds. Taken together, these data show that OA treatment of SH-SY5Y cells induces the appearance of HMW-TIP, which may represent tau oligomer or tau-crossreactive phospho-proteins. Our findings have implications for further studies of tau under the conditions of protein phosphatase downregulation.

neuroscience↗